Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial

作者：Domenica Lorusso, Yang Xiang, Kosei Hasegawa, Giovanni Scambia, Manuel Leiva, Pier Ramos-Elías, Alejandro Acevedo, Vladyslav Sukhin, Noelle Cloven, Andrea Juliana Gomes, Fernando Contreras Mejía, Ari Reiss, Ali̇ Ayhan, Jung‐Yun Lee, Valeriya Saevets, Flora Zagouri, Lucy Gilbert, Jalid Sehouli, Ekkasit Tharavichitkul, Kristina Lindemann, Roberta Lazzari, Chih‐Long Chang, Rudolf Lampé, Hong Zhu, Ana Oaknin, Melissa Christiaens, Stephan Polterauer, Tomoka Usami, Kan Li, Karin Yamada, Sarper Toker, Stephen J. O’Keefe, Sandro Pignata, Linda Duska · 发表于：The Lancet · 年份：2024 · DOI：10.1016/s0140-6736(24)00317-9 · 被引用次数：378 · 研究领域：Endometrial and Cervical Cancer Treatments、Cancer Immunotherapy and Biomarkers、Colorectal and Anal Carcinomas